The Federal Circuit’s March 19, 2008, decision in Amgen Inc. v. International Trade Commission, No: 2007-1014 (Fed. Cir. 2008), significantly expanded both the ITC’s jurisdiction to conduct investigations and the defenses available to some accused infringers.
This decision, by a split panel, will have important effects on the frequency and scope of Section 337 investigations of alleged patent infringement involving FDA-regulated products.
Read the complete article by clicking on the link below.
Reprinted with permission from Portfolio Media, Inc.
相关见解
December 10, 2025
Foley Viewpoints
NAIC Fall Meeting Update: Mental Health Parity and Addiction Equity Act (B) Working Group
The Mental Health Parity and Addiction Equity Act (B) Working Group (the “Working Group”) monitors developments related to the Mental…
December 10, 2025
Manufacturing Industry Advisor
The Auto Industry’s Talent War: Winning the Race for Skilled Workers
For over a century, the automotive sector was defined by mechanical engineering, fabrication, and assembly line mastery. But today, the industry is undergoing a technological transformation so profound it is rewriting the DNA of car manufacturing.
December 10, 2025
Foley Viewpoints
NAIC Fall Meeting Update: Climate and Resiliency (EX) Task Force
The mission of the Climate and Resiliency (EX) Task Force is to serve as the coordinating NAIC body for discussion and engagement on…